HN2008000817A - Derivados de oxadiazol - Google Patents
Derivados de oxadiazolInfo
- Publication number
- HN2008000817A HN2008000817A HN2008000817A HN2008000817A HN2008000817A HN 2008000817 A HN2008000817 A HN 2008000817A HN 2008000817 A HN2008000817 A HN 2008000817A HN 2008000817 A HN2008000817 A HN 2008000817A HN 2008000817 A HN2008000817 A HN 2008000817A
- Authority
- HN
- Honduras
- Prior art keywords
- receiver
- logo
- class
- crth2
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
Abstract
ESTA INVENCION SE REFIERE AL USO DE UAN CLASE DE COMPUESTOS QUE SON LIGANDOS DEL RECEPTOR CRTH2 (CHEMOATTRACTANT RECEPTOR - HOMOLOGUS MOLECULE EXPRESSED ON T HELPER CELLS TYPE 2, MOLECULA HOMO LOGA DE RECEPTOR QUIMIOTACTICO EXPRESADA EN CELULAS T COOPERADORAS DE TIPO 2), EN EL TRATAMIENTO DE ENFERMEDADES SENSIBLES A LA MODULACION DE LA ACTIVIDAD DEL RECEPTOR CRTH2, PRINCIPALMENTE ENFERMEDADES QUE TIENEN UN COMPONENTE INFLAMATORIO SIGNIFICATIVO. LA INVENCION TAMBIEN SE REFIERE A MIEMBROS NOVEDOSOS DE ESTA CLASE DE LIGANDOS Y A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0524428.0A GB0524428D0 (en) | 2005-11-30 | 2005-11-30 | Medicinal use of receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2008000817A true HN2008000817A (es) | 2010-10-01 |
Family
ID=35685792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2008000817A HN2008000817A (es) | 2005-11-30 | 2008-06-02 | Derivados de oxadiazol |
Country Status (17)
Country | Link |
---|---|
US (1) | US20080312220A1 (es) |
EP (1) | EP1960376A1 (es) |
JP (1) | JP2009517417A (es) |
KR (1) | KR20080072688A (es) |
CN (1) | CN101316829A (es) |
AU (1) | AU2006319462A1 (es) |
BR (1) | BRPI0619260A2 (es) |
CA (1) | CA2631652A1 (es) |
CR (1) | CR10034A (es) |
EA (1) | EA200801494A1 (es) |
EC (1) | ECSP088479A (es) |
GB (1) | GB0524428D0 (es) |
HN (1) | HN2008000817A (es) |
NO (1) | NO20082917L (es) |
SV (1) | SV2009002925A (es) |
WO (1) | WO2007062773A1 (es) |
ZA (1) | ZA200804687B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2327693E (pt) | 2007-12-14 | 2012-07-24 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
CA2751260A1 (en) | 2009-02-12 | 2010-08-19 | Stefano Crosignani | Phenoxy acetic acid derivatives |
WO2011108534A1 (ja) * | 2010-03-01 | 2011-09-09 | Shinozawa Takao | プロスタグランディンD2とその代謝物およびクレアチニンの分析による筋萎縮性側索硬化症(ALS)の診断方法、治療における薬物の有効性を評価する方法および尿中のtPGDM濃度を推測するシステム |
JP5800898B2 (ja) | 2010-07-05 | 2015-10-28 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 1−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンd2受容体調節剤としてのそれらの使用 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
KR20140107550A (ko) | 2011-12-21 | 2014-09-04 | 액테리온 파마슈티칼 리미티드 | 헤테로시클릴 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 그의 용도 |
EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
CN104744429B (zh) * | 2013-12-27 | 2016-09-28 | 启东韶远化学科技有限公司 | 一种环并[b]噻吩-3(2H)-酮-1,1-二氧化物的简单合成方法 |
ES2879826T3 (es) * | 2015-06-15 | 2021-11-23 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
WO2018170067A1 (en) * | 2017-03-14 | 2018-09-20 | Dana-Farber Cancer Institute, Inc. | Small molecule sensitization of bax activation for induction of cell death |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
TWI780281B (zh) * | 2017-12-14 | 2022-10-11 | 丹麥商Nmd藥品公司 | 用於治療神經肌肉病症的化合物 |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
GB2388540A (en) | 2002-05-17 | 2003-11-19 | Bayer Ag | New use of Ramatroban |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
US8022063B2 (en) * | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
-
2005
- 2005-11-30 GB GBGB0524428.0A patent/GB0524428D0/en not_active Ceased
-
2006
- 2006-11-22 EA EA200801494A patent/EA200801494A1/ru unknown
- 2006-11-22 WO PCT/EP2006/011216 patent/WO2007062773A1/en active Application Filing
- 2006-11-22 EP EP06829107A patent/EP1960376A1/en not_active Withdrawn
- 2006-11-22 KR KR1020087012911A patent/KR20080072688A/ko not_active Application Discontinuation
- 2006-11-22 CN CNA2006800441506A patent/CN101316829A/zh active Pending
- 2006-11-22 AU AU2006319462A patent/AU2006319462A1/en not_active Abandoned
- 2006-11-22 BR BRPI0619260-2A patent/BRPI0619260A2/pt not_active IP Right Cessation
- 2006-11-22 CA CA002631652A patent/CA2631652A1/en not_active Abandoned
- 2006-11-22 US US12/094,907 patent/US20080312220A1/en not_active Abandoned
- 2006-11-22 JP JP2008542640A patent/JP2009517417A/ja not_active Withdrawn
-
2008
- 2008-05-29 ZA ZA200804687A patent/ZA200804687B/xx unknown
- 2008-05-29 EC EC2008008479A patent/ECSP088479A/es unknown
- 2008-05-30 CR CR10034A patent/CR10034A/es not_active Application Discontinuation
- 2008-05-30 SV SV2008002925A patent/SV2009002925A/es not_active Application Discontinuation
- 2008-06-02 HN HN2008000817A patent/HN2008000817A/es unknown
- 2008-06-27 NO NO20082917A patent/NO20082917L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2006319462A1 (en) | 2007-06-07 |
EA200801494A1 (ru) | 2008-12-30 |
BRPI0619260A2 (pt) | 2011-09-27 |
ECSP088479A (es) | 2008-07-30 |
SV2009002925A (es) | 2009-01-05 |
CA2631652A1 (en) | 2007-06-07 |
CR10034A (es) | 2008-07-22 |
JP2009517417A (ja) | 2009-04-30 |
GB0524428D0 (en) | 2006-01-11 |
KR20080072688A (ko) | 2008-08-06 |
US20080312220A1 (en) | 2008-12-18 |
EP1960376A1 (en) | 2008-08-27 |
ZA200804687B (en) | 2009-10-28 |
CN101316829A (zh) | 2008-12-03 |
WO2007062773A1 (en) | 2007-06-07 |
NO20082917L (no) | 2008-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2008000817A (es) | Derivados de oxadiazol | |
CO6251377A2 (es) | Compuestos de imidazo | |
CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
CY1116700T1 (el) | Παρασκευη συνθετικου χολικου οξεος | |
UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
ECSP088558A (es) | Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa | |
UY28764A1 (es) | Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico | |
NI200700221A (es) | Antagonistas receptor pgd2 para el tratamiento de enfermedades inflamatorias | |
CR10694A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso | |
CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
AR055616A1 (es) | Compuestos de tiofeno bencimidazol | |
BRPI0605921B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
PE20030802A1 (es) | Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido | |
UY27732A1 (es) | Uso de análogos del benzimidazol en el tratamiento de la proliferación celular. | |
CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
ECSP055780A (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
PE20150758A1 (es) | Nuevos derivados biciclicos | |
ECSP055912A (es) | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas | |
SV1999000118A (es) | Nuevos derivados de pirazol substituidos ref. lea 33188-sv | |
AR047917A1 (es) | Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos | |
ATE488235T1 (de) | Neue 2-amino-benzimidazolderivate und ihre verwendung als modulatoren calciumaktivierter kaliumkanäle mit geringer leitfähigkeit | |
CR9649A (es) | Aminopirimidinas como modulares de cinasa | |
DOP2007000018A (es) | Moduladores de indol sulfonamida de receptores de progesterona | |
ES2319886T3 (es) | Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1). |